Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024GlobeNewsWire • 03/19/24
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of TherapyGlobeNewsWire • 03/07/24
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in HumansGlobeNewsWire • 03/05/24
Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor ConferenceGlobeNewsWire • 02/20/24
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024GlobeNewsWire • 02/14/24
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSDGlobeNewsWire • 02/12/24
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA ApprovalAccesswire • 02/01/24
Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVIDGlobeNewsWire • 01/31/24
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 01/29/24
Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.GlobeNewsWire • 01/25/24
Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of FibromyalgiaGlobeNewsWire • 01/09/24
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 TrialGlobeNewsWire • 01/03/24
Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 MillionGlobeNewsWire • 12/20/23
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 12/20/23
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SLAccesswire • 12/14/23
Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public MeetingGlobeNewsWire • 12/11/23
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in DecemberGlobeNewsWire • 11/28/23
Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 11/15/23
Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum DisorderGlobeNewsWire • 11/13/23
Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 11/09/23
Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical TrialsGlobeNewsWire • 11/02/23
